Simplex Trading Adds $462K in ADMA Biologics, Inc. ($ADMA)

Simplex Trading has taken a new position in ADMA Biologics, Inc. (NasdaqGM: ADMA), according to its latest 13F filing with the SEC. The firm added 54,917 shares of the biopharmaceutical company, valued around $473,934. This move marks a fresh investment in ADMA Biologics for Simplex Trading.

What Changed in Simplex Trading's ADMA Biologics Position

Simplex Trading's latest filing reveals a new position in ADMA Biologics, as the firm acquired 54,917 shares. Before this, Simplex Trading held no shares in the company. The investment, valued at approximately $473,934, indicates the firm's interest in the biopharmaceutical sector.

Other Institutional Activity in ADMA Biologics

Several other institutional investors have also been active in ADMA Biologics. BlackRock, Inc. increased its holdings by 497,449 shares, bringing its total to 36,830,774 shares worth about $331.8 million. State Street Corp added 486,946 shares, ending with 14,084,205 shares valued at approximately $126.9 million. Capital Research Global Investors significantly boosted their position by 4,553,644 shares, now holding 11,191,116 shares worth around $100.8 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both established new positions, with 10,306,871 and 8,868,657 shares valued at $92.9 million and $79.9 million, respectively. Nuveen, LLC also increased its holdings by 171,835 shares to 6,098,225 shares valued at $54.9 million.

ADMA Biologics Stock Snapshot

Shares of ADMA Biologics traded near $8.63. The company has a market cap of approximately $1.95 billion, with a P/E ratio of 12.38 and a forward P/E of 8.44. Its beta is 0.732, indicating less volatility compared to the market. The stock's 52-week range is between $7.21 and $20.46, with a 50-day moving average of $9.20 and a 200-day moving average of $14.37. ADMA's current ratio stands at 6.95, and its quick ratio is 3.73, reflecting strong liquidity, although its debt-to-equity ratio is relatively high at 110.67.

Recent Earnings

In its most recent earnings report, ADMA Biologics posted revenue of $509.9 million, reflecting a growth rate of 15.9%. The company achieved a net margin of 32.43% and a return on equity of 43.3%. Earnings per share were $0.68. The company is expected to release its next earnings report on August 5, 2026.

Insider Buying and Selling at ADMA Biologics, Inc.

Insider activity at ADMA Biologics shows that Jerrold Grossman made several purchases, acquiring 6,400 shares at $7.91 on May 27, 2026, and two separate purchases of 12,500 shares each at $8.01 on May 12 and May 11, 2026. Kaitlin Kestenberg-Messina, COO and SVP of Compliance, sold 20,362 shares at $9.11 on April 1, 2026. Lawrence Guiheen executed a trade on March 17, 2026, buying and selling 30,000 shares.

Analysts Set New Price Targets

Analysts remain bullish on ADMA Biologics. On May 7, 2026, Canaccord Genuity and Mizuho both maintained their 'buy' ratings, with target prices of $18.00 and $20.00, respectively. Canaccord Genuity also initiated coverage with a 'buy' rating and a $21.00 target on April 21, 2026. The consensus among analysts is a 'buy' rating, with a mean target price of $17.60 from five analyst opinions.

About ADMA Biologics

ADMA Biologics, Inc. is a biopharmaceutical company based in Ramsey, New Jersey. It develops, manufactures, and markets plasma-derived biologics aimed at treating immune deficiencies and infectious diseases. The company operates through its BioManufacturing and Plasma Collection Centers segments. Its products include BIVIGAM, ASCENIV, and Nabi-HB, which are used to treat various immune and infectious conditions. ADMA Biologics was founded in 2004 and is led by CEO Adam S. Grossman.

Bottom Line

Simplex Trading's new investment in ADMA Biologics highlights a fresh interest in the biotechnology sector. Investors often track such 13F filings to gauge institutional sentiment. However, it's important to remember that these filings reflect past positions and may not indicate current holdings. With a strong analyst outlook and recent insider activity, ADMA Biologics remains a company to watch in the healthcare space.